vs
Side-by-side financial comparison of Bilibili Inc. (BILI) and HAEMONETICS CORP (HAE). Click either name above to swap in a different company.
Bilibili Inc. is the larger business by last-quarter revenue ($1.3B vs $346.4M, roughly 3.7× HAEMONETICS CORP). HAEMONETICS CORP runs the higher net margin — 28.1% vs 6.0%, a 22.1% gap on every dollar of revenue. On growth, Bilibili Inc. posted the faster year-over-year revenue change (26.2% vs 4.8%). Over the past eight quarters, Bilibili Inc.'s revenue compounded faster (27.3% CAGR vs 1.5%).
Bilibili, nicknamed B Site, is a Chinese online video sharing website based in Shanghai where users can submit, view, and add overlaid commentary on videos.
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
BILI vs HAE — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.3B | $346.4M |
| Net Profit | $75.7M | $97.3M |
| Gross Margin | 37.0% | 57.2% |
| Operating Margin | 5.8% | 36.1% |
| Net Margin | 6.0% | 28.1% |
| Revenue YoY | 26.2% | 4.8% |
| Net Profit YoY | 143.0% | — |
| EPS (diluted) | $1.14 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $346.4M | ||
| Q4 25 | $1.3B | $339.0M | ||
| Q3 25 | $1.1B | $327.3M | ||
| Q2 25 | $1.0B | $321.4M | ||
| Q1 25 | $965.1M | $330.6M | ||
| Q4 24 | $1.0B | $348.5M | ||
| Q3 24 | $1.0B | $345.5M | ||
| Q2 24 | $843.1M | $336.2M |
| Q1 26 | — | $97.3M | ||
| Q4 25 | $75.7M | $44.7M | ||
| Q3 25 | $65.9M | $38.7M | ||
| Q2 25 | $30.5M | $34.0M | ||
| Q1 25 | $-1.5M | $58.0M | ||
| Q4 24 | $-176.0M | $37.5M | ||
| Q3 24 | $11.4M | $33.8M | ||
| Q2 24 | $83.7M | $38.4M |
| Q1 26 | — | 57.2% | ||
| Q4 25 | 37.0% | 59.7% | ||
| Q3 25 | 36.7% | 59.5% | ||
| Q2 25 | 36.5% | 59.8% | ||
| Q1 25 | 36.3% | 58.4% | ||
| Q4 24 | 36.2% | 55.5% | ||
| Q3 24 | 34.9% | 54.2% | ||
| Q2 24 | 29.9% | 52.0% |
| Q1 26 | — | 36.1% | ||
| Q4 25 | 5.8% | 19.9% | ||
| Q3 25 | 4.6% | 17.9% | ||
| Q2 25 | 3.4% | 16.8% | ||
| Q1 25 | 0.2% | 21.6% | ||
| Q4 24 | -16.0% | 16.9% | ||
| Q3 24 | 0.9% | 15.0% | ||
| Q2 24 | 9.5% | 11.8% |
| Q1 26 | — | 28.1% | ||
| Q4 25 | 6.0% | 13.2% | ||
| Q3 25 | 6.1% | 11.8% | ||
| Q2 25 | 3.0% | 10.6% | ||
| Q1 25 | -0.2% | 17.5% | ||
| Q4 24 | -17.5% | 10.8% | ||
| Q3 24 | 1.1% | 9.8% | ||
| Q2 24 | 9.9% | 11.4% |
| Q1 26 | — | — | ||
| Q4 25 | $1.14 | $0.95 | ||
| Q3 25 | $1.05 | $0.81 | ||
| Q2 25 | $0.51 | $0.70 | ||
| Q1 25 | $0.00 | $1.17 | ||
| Q4 24 | $0.21 | $0.74 | ||
| Q3 24 | $-0.03 | $0.66 | ||
| Q2 24 | $-0.20 | $0.74 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.7B | $245.4M |
| Total DebtLower is stronger | $1.4B | $1.2B |
| Stockholders' EquityBook value | $2.2B | $796.3M |
| Total Assets | $5.9B | $2.4B |
| Debt / EquityLower = less leverage | 0.62× | 1.53× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $245.4M | ||
| Q4 25 | $2.7B | $363.4M | ||
| Q3 25 | $2.4B | $296.4M | ||
| Q2 25 | — | $292.9M | ||
| Q1 25 | $1.9B | $306.8M | ||
| Q4 24 | $1.8B | $320.8M | ||
| Q3 24 | $11.7B | $299.3M | ||
| Q2 24 | — | $344.4M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $1.4B | $1.2B | ||
| Q3 25 | $1.4B | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | $700.3M | $1.2B | ||
| Q4 24 | $662.5M | — | ||
| Q3 24 | $4.3B | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $796.3M | ||
| Q4 25 | $2.2B | $911.5M | ||
| Q3 25 | $2.1B | $849.2M | ||
| Q2 25 | — | $882.3M | ||
| Q1 25 | $2.0B | $820.8M | ||
| Q4 24 | $1.9B | $906.9M | ||
| Q3 24 | $13.7B | $878.9M | ||
| Q2 24 | — | $905.4M |
| Q1 26 | — | $2.4B | ||
| Q4 25 | $5.9B | $2.5B | ||
| Q3 25 | $5.6B | $2.4B | ||
| Q2 25 | — | $2.5B | ||
| Q1 25 | $4.6B | $2.5B | ||
| Q4 24 | $4.5B | $2.5B | ||
| Q3 24 | $32.0B | $2.5B | ||
| Q2 24 | — | $2.5B |
| Q1 26 | — | 1.53× | ||
| Q4 25 | 0.62× | 1.34× | ||
| Q3 25 | 0.65× | 1.44× | ||
| Q2 25 | — | 1.39× | ||
| Q1 25 | 0.35× | 1.49× | ||
| Q4 24 | 0.34× | — | ||
| Q3 24 | 0.31× | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $263.1M | $293.2M |
| Free Cash FlowOCF − Capex | — | $209.9M |
| FCF MarginFCF / Revenue | — | 60.6% |
| Capex IntensityCapex / Revenue | — | 9.5% |
| Cash ConversionOCF / Net Profit | 3.47× | 3.01× |
| TTM Free Cash FlowTrailing 4 quarters | — | $417.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $293.2M | ||
| Q4 25 | $263.1M | $93.6M | ||
| Q3 25 | $283.2M | $111.3M | ||
| Q2 25 | $277.7M | $17.4M | ||
| Q1 25 | $179.4M | $116.6M | ||
| Q4 24 | $191.9M | $43.8M | ||
| Q3 24 | $2.2B | $48.8M | ||
| Q2 24 | — | $-27.4M |
| Q1 26 | — | $209.9M | ||
| Q4 25 | — | $87.2M | ||
| Q3 25 | — | $106.3M | ||
| Q2 25 | — | $13.6M | ||
| Q1 25 | $174.5M | $100.9M | ||
| Q4 24 | — | $35.2M | ||
| Q3 24 | — | $39.4M | ||
| Q2 24 | — | $-33.1M |
| Q1 26 | — | 60.6% | ||
| Q4 25 | — | 25.7% | ||
| Q3 25 | — | 32.5% | ||
| Q2 25 | — | 4.2% | ||
| Q1 25 | 18.1% | 30.5% | ||
| Q4 24 | — | 10.1% | ||
| Q3 24 | — | 11.4% | ||
| Q2 24 | — | -9.8% |
| Q1 26 | — | 9.5% | ||
| Q4 25 | — | 1.9% | ||
| Q3 25 | — | 1.5% | ||
| Q2 25 | — | 1.2% | ||
| Q1 25 | 0.5% | 4.7% | ||
| Q4 24 | — | 2.5% | ||
| Q3 24 | — | 2.7% | ||
| Q2 24 | — | 1.7% |
| Q1 26 | — | 3.01× | ||
| Q4 25 | 3.47× | 2.09× | ||
| Q3 25 | 4.30× | 2.88× | ||
| Q2 25 | 9.11× | 0.51× | ||
| Q1 25 | — | 2.01× | ||
| Q4 24 | — | 1.17× | ||
| Q3 24 | 195.23× | 1.44× | ||
| Q2 24 | — | -0.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BILI
| Value-added services (VAS) | $466.4M | 37% |
| Advertising | $435.0M | 34% |
| Mobile games | $220.3M | 17% |
| Other | $80.8M | 6% |
| IP derivatives and others | $68.2M | 5% |
HAE
| Hospital | $159.6M | 46% |
| Plasma | $130.3M | 38% |
| Blood Center | $56.4M | 16% |
